Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Development expenses by Quarter
Development expenses (clinical trials, regulatory & CMC) — Total ($M) ($M)
Vertex Pharmaceuticals Development expenses: $787M in Q2 2026, up 2.3% from a year earlier.
Where the Q2 2026 figure comes from
“|| Total development expenses | $ 786.5 | $ 769.1 | 2% | $ 1,543.1 | $ 1,542.7 | —%”
Source: Form 10-Q (vrtx-20260630.htm, filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K MD&A & Note (Segment Significant Expenses).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up development expenses
- Development — Outsourced clinical trials, CROs, manufacturing & other direct costs ($M)368 · Q2 2026
- Development — Salary and employee benefits ($M)194 · Q2 2026
- Development — Stock-based compensation expense ($M)83.2 · Q2 2026
- Development — Infrastructure and facilities costs ($M)142 · Q2 2026
- Development — Outsourced services ex-drug supply (FY2013–FY2018, $M)84.8 · Q4 2018
- Development — Clinical drug supply & lab supplies (standalone through FY2018, $M)24.8 · Q4 2018
Cite this data
StockData. (2026). Vertex Pharmaceuticals Development expenses ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rd-dev-total
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.